Celsius Therapeutics
Edit info- Founded: 2017
- Location: Cambridge, MA
- Employee range: 1 - 10
- Clinical stage: Clin1
- Therapy area: IBD
- Drug types: GI, IMM
- Lead product: CEL383
- Funding: $83M Mar 2022; $65M A May 2018
- Investors: Third Rock
celsiustx.com linkedin.com job board
Business:
RNA sequencing for drug discovery, Antibody-drug conjugates
Drug notes:
Undisclosed RD IBD
About:
Celsius Therapeutics is leveraging the power of Single Cell Genomics and Machine Learning to develop precision medicines for cancer and autoimmune diseases. Dysfunctional cells can cause disease, but the exact problematic cells and their effect is often unclear. By looking at the genes expressed in single cells in their natural context, Celsius is developing machine learning algorithms to identify the specific cells that cause the disease and which genes/pathways are responsible. This helps to identify the best choices for drug combinations. With their global reach of tissue samples, industrialized workflow, and deep insights, Celsius’ mission is to develop life-saving medicines and discover critical biomarkers for better patient care by understanding the ecosystem of disease.
Jobs:
News:
Celsius Therapeutics Names Scientific Advisers - Business Wire
googlenews
Sep 22, 2022
New hires
external-link
Johnson & Johnson partners with Celsius Therapeutics in large-scale test of single-cell sequencing - STAT
googlenews
Jul 9, 2019
Science/business updates
external-link
Celsius Therapeutics is now part of AbbVie. Learn more and follow AbbVie here: https://lnkd.in/e3nJiUiu
linkedin
Jul 19, 2024
Science/business updates
external-link
AbbVie Announces Emotional Impact Report on Mental Health of Underrepresented CLL Cancer Patients
web
Dec 19, 2024
Science/business updates
external-link
AbbVie buys drug developer Celsius Therapeutics for $250 million
crunchbase
Jun 30, 2024
Funding-related
external-link
The Big Deal: Curie.Bio brings coaching to early-stage biotech - - Global Corporate Venturing
googlenews
Feb 17, 2023
Funding-related
external-link
Single-cell massively-parallel multiplexed microbial ...
crunchbase
Aug 31, 2023
Science/business updates
external-link
Colorectal cancer: discover our partnership with Celsius Therapeutics in video - Servier
googlenews
Mar 31, 2022
Science/business updates
external-link
Two Data Analyses From Clinical Trials Show Epcoritamab (DuoBody® CD3xCD20) Induces Durable Complete Reponses As Monotherapy and Combination Treatment in Patients With Diffuse Large B-Cell Lymphoma
web
Dec 19, 2024
Science/business updates
external-link
Solu Therapeutics Appoints Michael Boretti, Ph.D., as Chief Business Officer - Business Wire
googlenews
Mar 19, 2024
New hires
external-link
Celsius Therapeutics Highlights Recent Accomplishments and Key Initiatives for 2022 - Business Wire
googlenews
Mar 24, 2022
Science/business updates
external-link
PharmaVOICE 100 Who’s on the List - By Category - PharmaVoice
googlenews
Aug 1, 2020
New hires
external-link
AbbVie Announces Positive Topline Results for the Phase 3 TEMPO-2 Trial Evaluating Tavapadon as a Monotherapy for Parkinson's Disease
web
Dec 19, 2024
Science/business updates
external-link
AbbVie to Acquire Nimble Therapeutics, Further Strengthening Immunology Pipeline
web
Dec 19, 2024
Funding-related
external-link
AbbVie sweeps up inflammatory-focused Celsius for $250M cash in summer heat wave
crunchbase
Jun 30, 2024
Funding-related
external-link
AbbVie to buy Cambridge biotech Celsius for $250 million - The Boston Globe
googlenews
Jun 27, 2024
Funding-related
external-link
AAPS PharmSci 360: Advancements and Challenges in Large RNA Therapeutics - Pharmaceutical Technology Magazine
googlenews
Oct 20, 2024
Science/business updates
external-link
Celsius Therapeutics appoints Sarah Grant as CMO - The Pharma Letter
googlenews
Aug 26, 2022
New hires
external-link
AbbVie's (ABBV) Celsius Therapeutics Deal to Boost IBD Presence
crunchbase
Jun 30, 2024
Science/business updates
external-link
AbbVie to buy Cambridge biotech Celsius for $250 million
crunchbase
Jun 30, 2024
Funding-related
external-link
AbbVie buys drug developer Celsius Therapeutics for $250 million - Crain's Chicago Business
googlenews
Jun 27, 2024
Funding-related
external-link
Biotech layoffs 2023: In Q3, more than 1,000 workers lost their ...
crunchbase
Oct 2, 2023
New hires
external-link
Fierce Biotech Layoff Tracker 2023: Reneo reduces workforce by 70%; Oxurion cuts staff down to 10 - Fierce Biotech
googlenews
Dec 29, 2023
New hires
external-link
Allergan Aesthetics Offers Free Business Education Courses Online to Support Growing Practices with Allergan Aesthetics Products
web
Dec 19, 2024
Science/business updates
external-link
PRNewswire
web
Dec 20, 2024
I don't have enough information to classify this title. The title "PRNewswire" appears to be a news wire service rather than a specific news article. Can you provide the actual news title?
external-link
TREM-1 as a novel therapeutic target for the treatment of inflammatory bowel diseases - BioWorld Online
googlenews
Mar 6, 2023
Science/business updates
external-link
Celsius Therapeutics inks first biopharma deal—an IBD study with Janssen - Fierce Biotech
googlenews
Jul 9, 2019
Science/business updates
external-link
AbbVie sweeps up inflammatory-focused Celsius for $250M cash in summer heat wave - Fierce Biotech
googlenews
Jun 27, 2024
Funding-related
external-link
AbbVie Acquires Celsius Therapeutics, Gains Anti-Inflammatory Disease Antibody - BioPharm International
googlenews
Jun 28, 2024
Science/business updates
external-link
AbbVie Expands IBD Drug Pipeline Again With $250M Celsius Therapeutics Acquisition
crunchbase
Jun 30, 2024
Funding-related
external-link
J&J’s Janssen Doubles Down on Bioinformatics with Celsius Therapeutics Partnership - BioSpace
googlenews
Jul 9, 2019
Science/business updates
external-link
AbbVie pays $250 million to acquire Celsius Therapeutics - The Business Journals
googlenews
Jun 27, 2024
Funding-related
external-link
AbbVie Pays $250M for Celsius and Its Lead Anti-TREM1 Antibody for IBD - Inside Precision Medicine
googlenews
Jun 28, 2024
Funding-related
external-link
Celsius Nets $83M to Bring Precision IBD Treatment to Trial - BioSpace
googlenews
Mar 24, 2022
Funding-related
external-link
Celsius turns up the heat with lead drug selection, $83M financing - Fierce Biotech
googlenews
Mar 24, 2022
Funding-related
external-link
AbbVie acquires IBD therapeutics maker Celsius for $250m - World Pharmaceutical Frontiers
googlenews
Jun 28, 2024
Funding-related
external-link
Celsius Therapeutics Launches with $65 Million Series A - BioSpace
googlenews
May 15, 2018
Funding-related
external-link
Broad Institute Spinout Aims To Bring Precision Medicine To Autoimmune Disease - Forbes
googlenews
May 15, 2018
Science/business updates
external-link
Artificial Intelligence in Drug Discovery Market is Expected to ...
crunchbase
Dec 18, 2023
Science/business updates
external-link
AbbVie Completes Acquisition of Aliada Therapeutics
web
Dec 19, 2024
Science/business updates
external-link
AbbVie turns up the heat with $250M Celsius buy
fiercebiotech.com
Dec 19, 2024
Funding-related
external-link
AbbVie completes acquisition of Celsius Therapeutics for $250m - Yahoo Finance
googlenews
Jun 28, 2024
Funding-related
external-link
AbbVie buys Roche spinout Nimble Therapeutics for $200M - Fierce Biotech
googlenews
Dec 13, 2024
Funding-related
external-link
Celsius Therapeutics initiates dosing in trial of IBD therapy - Clinical Trials Arena
googlenews
Aug 4, 2023
Science/business updates
external-link
FierceBiotech's 2019 Fierce 15 - Fierce Biotech
googlenews
Sep 23, 2019
Science/business updates
external-link
JPM: What does a virtual J.P. Morgan healthcare conference mean for the future of the meeting? Executives weigh in - Fierce Biotech
googlenews
Jan 12, 2021
Science/business updates
external-link
Celsius turns up the heat with lead drug selection, $83M ...
fiercebiotech.com
Dec 19, 2024
Funding-related
external-link
Can single-cell genomics lead to a new wave of drug targets? Celsius Therapeutics thinks so - Chemical & Engineering News
googlenews
May 15, 2018
Science/business updates
external-link
AbbVie expands its IBD prospects with $250M Celsius deal - BioPharma Dive
googlenews
Jun 27, 2024
Funding-related
external-link
AbbVie acquires Celsius Therapeutics - The Pharma Letter
googlenews
Jun 28, 2024
Funding-related
external-link
AbbVie Receives European Commission Approval of ELAHERE® (mirvetuximab soravtansine) for the Treatment of Platinum-Resistant Ovarian Cancer
web
Dec 19, 2024
Science/business updates
external-link
AbbVie Buys Celsius Therapeutics for $250 Million
crunchbase
Jun 27, 2024
Funding-related
external-link
AbbVie to Present at Citi's 2024 Global Healthcare Conference
web
Dec 19, 2024
Science/business updates
external-link
AbbVie places small outlay on deal to buy Nimble Therapeutics - FirstWord Pharma
googlenews
Dec 13, 2024
Funding-related
external-link
AbbVie Expands IBD Drug Pipeline Again With $250M Celsius Therapeutics Acquisition - MedCity News
googlenews
Jun 30, 2024
Funding-related
external-link
AbbVie buys Third Rock’s Celsius for $250M to expand IBD pipeline - Endpoints News
googlenews
Jun 27, 2024
Funding-related
external-link
AbbVie Awards 20 Individuals Living With Migraine To Support Career Aspirations
web
Dec 19, 2024
Funding-related
external-link
Crohn's Disease Therapeutics Market Size Report, 2030 - Grand View Research
googlenews
Aug 3, 2018
Science/business updates
external-link
Celsius Therapeutics Signs Collaboration Agreement with Janssen to Identify Response Biomarkers for Ulcerative Colitis - Business Wire
googlenews
Jul 9, 2019
Science/business updates
external-link
Single-Cell Analysis for Precision Medicine: Tariq Kassum on The Long Run - Timmerman Report
googlenews
Oct 26, 2022
Science/business updates
external-link
Celsius Therapeutics Announces Key Leadership Appointments - Business Wire
googlenews
May 12, 2020
New hires
external-link
Investigational Epcoritamab (DuoBody® CD3xCD20) Combination Therapy Shows High Response Rates in Clinical Trial of Patients With Relapsed or Refractory (R/R) Follicular Lymphoma (FL)
web
Dec 19, 2024
Science/business updates
external-link
elluminate® Clinical Data Platform from eClinical Solutions Selected by Celsius Therapeutics to Speed Insights & Value of Clinical Data
crunchbase
Dec 3, 2020
Science/business updates
external-link
Chutes & Ladders—Former Takeda exec takes reins at Tessa - Fierce Biotech
googlenews
Aug 26, 2022
New hires
external-link
Celsius bags $65M to develop precision drugs for cancer, autoimmune disease - Fierce Biotech
googlenews
May 15, 2018
Funding-related
external-link
AbbVie pays $250M to acquire Cambridge biotech - The Business Journals
googlenews
Jun 27, 2024
Funding-related
external-link
AbbVie acquires biotech Celsius Therapeutics for $250m - Pharmaceutical Technology
googlenews
Jun 28, 2024
Funding-related
external-link
Celsius Therapeutics Announces Initiation of Dosing in Phase 1 Clinical Trial of CEL383, an Anti-TREM1 Antibody for the Treatment of Inflammatory Bowel Disease - Business Wire
googlenews
Aug 3, 2023
Science/business updates
external-link
Celsius Therapeutics Appoints Sarah Grant, M.D., as Chief Medical Officer
crunchbase
Aug 25, 2022
New hires
external-link
Celsius bags $65M to develop precision drugs for cancer ...
fiercebiotech.com
Dec 19, 2024
Funding-related
external-link
Celsius Therapeutics inks first biopharma deal—an IBD ...
fiercebiotech.com
Dec 19, 2024
Science/business updates
external-link
AbbVie expands inflammatory disease pipeline with $250m Celsius acquisition - PMLiVE
googlenews
Jun 28, 2024
Funding-related
external-link
AbbVie Expands Immuno Portfolio With $250M Celsius Buy as Humira Hits Patent Cliff - BioSpace
googlenews
Jun 28, 2024
Funding-related
external-link
Dozens more biotech jobs axed as two firms make cuts - The Business Journals
googlenews
Aug 3, 2023
Science/business updates
external-link
© 2024 Work In Biotech LLC
Personal dataTerms of ServicePrivacy PolicyContact: recruit@workinbiotech.com
Personal dataTerms of ServicePrivacy PolicyContact: recruit@workinbiotech.com